Cash Flow from Investing Activities: The total change in cash resulting from a company's investments.
Nektar Therapeutics (NKTR) had Cash Flow from Investing Activities of $-350.79M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$10.86M |
|
$-44.90M |
|
-- |
|
$10.86M |
|
$49.91M |
|
$-39.05M |
|
$-4.04M |
|
$-43.09M |
|
$-43.09M |
|
$-43.15M |
|
$-44.90M |
|
$-44.90M |
|
$-43.15M |
|
$-39.05M |
|
$-40.57M |
|
24.74M |
|
24.74M |
|
$-1.82 |
|
$-1.82 |
|
| Balance Sheet Financials | |
$589.04M |
|
-- |
|
$174.23M |
|
$763.27M |
|
$57.71M |
|
-- |
|
$129.35M |
|
$187.06M |
|
$576.22M |
|
$576.22M |
|
$576.22M |
|
29.47M |
|
| Cash Flow Statement Financials | |
$-44.30M |
|
|
Cash Flow from Investing Activities |
$-350.79M |
$529.55M |
|
$15.12M |
|
$149.58M |
|
$134.46M |
|
$3.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-359.58% |
|
-359.58% |
|
-- |
|
-396.74% |
|
-413.44% |
|
$-44.32M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-7.79% |
|
-7.79% |
|
-5.88% |
|
-7.79% |
|
$19.55 |
|
$-1.79 |
|
$-1.79 |
|